Tag: research

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

According to Pixalate’s latest Supply Path Optimization (SPO) research using SupplyChain Object (SCO) data, an estimated $880 million in global web open programmatic ad spend is routed through unauthorized sellers; unauthorized direct seller web traffic saw a 159% higher IVT, including ad fraud

According to Pixalate’s latest Supply Path Optimization (SPO) research using SupplyChain Object (SCO) data, an estimated $652 million in global CTV open programmatic ad spend is routed through unauthorized sellers; 28% of Connected TV (CTV) traffic with SCOs marked as ‘complete’ was sold by unauthorized direct sellers

According to Pixalate’s latest Supply Path Optimization (SPO) research using SupplyChain Object (SCO) data, an estimated $3.15 billion in global CTV open programmatic ad spend is routed through unauthorized sellers; 9% of mobile in-app traffic with SCOs marked as ‘complete’ was sold by unauthorized direct sellers

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.

Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription